Massive new study tracks MG care across china

NCT ID NCT06700616

Ongoing Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 12, 2026 · Updated 20 times

Summary

This study is observing about 1,200 people with myasthenia gravis (MG) in China to understand how doctors currently treat the disease and how patients feel over time. Participants will have check-ups every 6 months until the end of 2027. The goal is to learn more about real-world treatments and outcomes, not to test a new drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Beijing, China
Research Site

Chengdu, China
Research Site

Fuzhou, China
Research Site

Guangzhou, China
Research Site

Guiyang, China
Research Site

Harbin, China
Research Site

Hebei, China
Research Site

Henan, China
Research Site

Inner Mongolia, China
Research Site

Jiangsu, China
Research Site

Lanzhou, China
Research Site

Nanning, China
Research Site

Qingdao, China
Research Site

Taiyuan, China
Research Site

Tianjin, China
Research Site

Ürümqi, China
Research Site

Wenzhou, China
Research Site

Wuhan, China
Research Site

Xi'an, China
Research Site

Yinchuan, China

Conditions

Explore the condition pages connected to this study.

MYASTHENIA GRAVIS